Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections
Vaccines against parasites have lagged centuries behind those against viral and bacterial infections, despite the devastating morbidity and widespread effects of parasitic diseases across the globe. One of the greatest hurdles to parasite vaccine development has been the lack of vaccine strategies a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/16/3/334 |
| _version_ | 1797609551479963648 |
|---|---|
| author | Cal Koger-Pease Dilhan J. Perera Momar Ndao |
| author_facet | Cal Koger-Pease Dilhan J. Perera Momar Ndao |
| author_sort | Cal Koger-Pease |
| collection | DOAJ |
| description | Vaccines against parasites have lagged centuries behind those against viral and bacterial infections, despite the devastating morbidity and widespread effects of parasitic diseases across the globe. One of the greatest hurdles to parasite vaccine development has been the lack of vaccine strategies able to elicit the complex and multifaceted immune responses needed to abrogate parasitic persistence. Viral vectors, especially adenovirus (AdV) vectors, have emerged as a potential solution for complex disease targets, including HIV, tuberculosis, and parasitic diseases, to name a few. AdVs are highly immunogenic and are uniquely able to drive CD8+ T cell responses, which are known to be correlates of immunity in infections with most protozoan and some helminthic parasites. This review presents recent developments in AdV-vectored vaccines targeting five major human parasitic diseases: malaria, Chagas disease, schistosomiasis, leishmaniasis, and toxoplasmosis. Many AdV-vectored vaccines have been developed for these diseases, utilizing a wide variety of vectors, antigens, and modes of delivery. AdV-vectored vaccines are a promising approach for the historically challenging target of human parasitic diseases. |
| first_indexed | 2024-03-11T06:03:00Z |
| format | Article |
| id | doaj.art-298670b987e94badbb0915d8b70bb9e6 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-11T06:03:00Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-298670b987e94badbb0915d8b70bb9e62023-11-17T13:11:21ZengMDPI AGPharmaceuticals1424-82472023-02-0116333410.3390/ph16030334Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic InfectionsCal Koger-Pease0Dilhan J. Perera1Momar Ndao2Division of Experimental Medicine, McGill University, Montreal, QC H3A 3J1, CanadaDivision of Experimental Medicine, McGill University, Montreal, QC H3A 3J1, CanadaDivision of Experimental Medicine, McGill University, Montreal, QC H3A 3J1, CanadaVaccines against parasites have lagged centuries behind those against viral and bacterial infections, despite the devastating morbidity and widespread effects of parasitic diseases across the globe. One of the greatest hurdles to parasite vaccine development has been the lack of vaccine strategies able to elicit the complex and multifaceted immune responses needed to abrogate parasitic persistence. Viral vectors, especially adenovirus (AdV) vectors, have emerged as a potential solution for complex disease targets, including HIV, tuberculosis, and parasitic diseases, to name a few. AdVs are highly immunogenic and are uniquely able to drive CD8+ T cell responses, which are known to be correlates of immunity in infections with most protozoan and some helminthic parasites. This review presents recent developments in AdV-vectored vaccines targeting five major human parasitic diseases: malaria, Chagas disease, schistosomiasis, leishmaniasis, and toxoplasmosis. Many AdV-vectored vaccines have been developed for these diseases, utilizing a wide variety of vectors, antigens, and modes of delivery. AdV-vectored vaccines are a promising approach for the historically challenging target of human parasitic diseases.https://www.mdpi.com/1424-8247/16/3/334adenovirus vaccinesparasitesprotozoahelminthvaccine vector |
| spellingShingle | Cal Koger-Pease Dilhan J. Perera Momar Ndao Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections Pharmaceuticals adenovirus vaccines parasites protozoa helminth vaccine vector |
| title | Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections |
| title_full | Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections |
| title_fullStr | Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections |
| title_full_unstemmed | Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections |
| title_short | Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections |
| title_sort | recent advances in the development of adenovirus vectored vaccines for parasitic infections |
| topic | adenovirus vaccines parasites protozoa helminth vaccine vector |
| url | https://www.mdpi.com/1424-8247/16/3/334 |
| work_keys_str_mv | AT calkogerpease recentadvancesinthedevelopmentofadenovirusvectoredvaccinesforparasiticinfections AT dilhanjperera recentadvancesinthedevelopmentofadenovirusvectoredvaccinesforparasiticinfections AT momarndao recentadvancesinthedevelopmentofadenovirusvectoredvaccinesforparasiticinfections |